Conduit Pharmaceuticals Inc. (CDT) - Total Liabilities
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has total liabilities worth $2.12 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CDT long-term investment intensity to see how much of total assets are deployed in long-term investments.
Conduit Pharmaceuticals Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Conduit Pharmaceuticals Inc. total assets.
Conduit Pharmaceuticals Inc. Competitors by Total Liabilities
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vistal Gdynia
WAR:VTL
|
Poland | zł565.15 Million |
|
Hansa Trust
LSE:HAN
|
UK | GBX46.84 Million |
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
UK | GBX42.25 Million |
|
Curis Inc
NASDAQ:CRIS
|
USA | $16.98 Million |
|
Transition Evergreen
PA:EGR
|
France | €56.53 Million |
|
FAT Brands Inc
NASDAQ:FAT
|
USA | $1.80 Billion |
|
Riwi Corp
V:RIWI
|
Canada | CA$2.46 Million |
|
Concurrent Technologies Plc
LSE:CNC
|
UK | GBX10.01 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Conduit Pharmaceuticals Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CDT net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Conduit Pharmaceuticals Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual total liabilities of Conduit Pharmaceuticals Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.28 Billion | +20646.38% |
| 2024-12-31 | $10.99 Million | +43.03% |
| 2023-12-31 | $7.68 Million | -23.91% |
| 2022-12-31 | $10.09 Million | +5143.47% |
| 2021-12-31 | $192.51K | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more